What would you like to look for?
Site search
22 January 2024

GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyer Squibb (BMS) to further support the development of its innovative platform to enable high-throughput design and production of drug development candidates for fast and deep degradation of pathogenic proteins. VISCHER advises GlycoEra on all legal issues related to the transaction.

The VISCHER team includes Matthias Staehelin (Partner, Corporate/M&A), Pauline Pfirter (Senior Associate, Corporat/M&A) and Timothy Woodtli (Associate, Corporate/M&A).

Authors: Matthias Staehelin, Pauline Pfirter and Timothy Woodtli